DOCSLIB.ORG

Dihydrotestosterone (Adractim®) 2.5% Gel for Topical Application

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dihydrotestosterone (Adractim®) 2.5% Gel for Topical Application d g t squeezin l aa StSt gelgel Star gel from this en 0mg0m0mg 2.2.55 5mg5mg 7.7.55 10m1 mg l l 12.12.55 ge g ge ) 15m15mg f 17.17.55 ® 20m20mg g g o 22.22.55 25 25m25mg 1.25 g of g 1.25 1 1.25 1 1 1.25 g of g 1.25 27.5 30mg300mm 32.32.5.5 35m35mg drotestosterone hy 37.5 Put on a pair of gloves Gently squeeze the gel onto the mark on the ruler illustrated below – as instructed on the dispensing label. Leave for five minutes Wipe this laminated information sheet with a damp piece of kitchen paper ready for the next dose. Remove the gloves and wash them in warm soapy water ready for the next dose. of di 40m40mg © GOSH NHS Foundation Trust January 2016 © GOSH NHS Foundation Trust How is it used? Dihydrotestosterone 2.5% gel is for external It should be applied over the use only. required area of skin after washing. The gel should be left to dry for five minutes or so before putting on clothes. 1. 2. 3. Spread over the required area evenly 4. 5. Note: Dihydrotestosterone 2.5% gel should not be applied to any broken areas of skin. 42.42.55 l l 45mg45m45m ge ge 47.47.55 , ® 50mg50mm 52.52.55 55mg55mm 57.57.55 2.5 g of g 2 2.5 2 2.5 g of g 2.5 60mg600m0m 62.62.5.5 Dihydrotestosterone is a synthetic version of a hormone called testosterone. It is available as a 2.5% gel under the brand name Adractim What is dihydrotestosterone? which is imported from abroad. It is used for children with hormone deficiencies. It works either by correcting the hormone deficiency, in a particular part of the body or affecting the body as a whole Ref: 2015F0390 Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families NHS Foundation Trust: Hospital for Children Ormond Street Great numbers on this information sheet. ask your doctor, nurse or pharmacist or telephone one of the contact nurse or pharmacist or ask your doctor, side effect mentioned. If you have any questions or concerns, side effect please differently to medicines, so your child will not necessarily suffer every to medicines, so your child will not necessarily suffer differently it is used and some of the possible side effects. Each person reacts Each person reacts possible side effects. it is used and some of the This information sheet explains what andractim 2.5% gel is, how with any information provided by the manufacturer. This information sheet should be read in conjunction This information sheet should be read in conjunction 2.5% gel for topical application Dihydrotestosterone (Adractim Dihydrotestosterone Sheet 1 of 2 Who should not use Dihydrotestosterone 2.5% gel Dihydrotestosterone 2.5% gel? and other medicines People who are hypersensitive to Dihydrotestosterone is applied externally so it Dihydrotestosterone or its excipients (Carbomer should not react with any other medicines. 934, triethanolamine, Alcohol 95%) should Important information discuss using this medicine with their doctor. n As this is a specialist treatment, GOSH or your local hospital will supply your child’s What are the side effects? medicine. The following side effects are rare and are n Keep medicines in a safe place where usually due to the dose being too high, so will children cannot reach them. disappear when the dosage is reduced. n Keep the gel at room temperature, away n Mood swings and irritability from bright light or direct sunlight and away from heat. Do not store in the fridge. n Excessive energy or signs of being hyperactive n If the doctor decides that your child should stop using dihydrotestosterone, return any n Weight gain remaining gel to your pharmacist. Do not n Extra hair growth throw away. n Hoarseness n Oily skin n Acne Useful numbers GOSH switchboard: 020 7405 9200 Endocrinology Clinical Nurse Specialists: 020 7813 8214 Pharmacy medicines information: 020 7829 8608 from Monday to Friday from 9am to 5pm Compiled by the Pharmacy department in collaboration with the Child and Family Information Group Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London WC1N 3JH www.gosh.nhs.uk Sheet 2 of 2 Ref: 2015F0390 © GOSH NHS Foundation Trust January 2016.
Load more

Recommended publications
  • Dehydroepiandrosterone – Is the Fountain of Youth Drying Out?
    Physiol. Res. 52: 397-407, 2003 MINIREVIEW Dehydroepiandrosterone – Is the Fountain of Youth Drying Out? P. CELEC 1,2, L. STÁRKA3 1Faculty of Medicine, 2Faculty of Natural Sciences, Comenius University, Bratislava, Slovakia and 3Institute of Endocrinology, Prague, Czech Republic Received September 15, 2002 Accepted October 7, 2002 Summary Dehydroepiandrosterone (DHEA) and its sulphate-bound form (DHEAS) are important steroids mainly of adrenal origin. Their physiological and pathophysiological functions are not yet fully identified, although a number of various possible features have been hypothesized. Most popular is the description of the “hormone of youth” as the long-term dynamics of DHEA levels are characterized by a sharp age-related decline in the late adulthood and later. Low levels of DHEA are, however, associated not only with the ageing process but also with diabetes mellitus, cardiovascular diseases and some neurological or immunological entities. In the past decade, a number of brief studies have concentrated on these relationships and also on the role of exogenous DHEA in health, disease and human well-being. This article tries to summarize some of the most important facts achieved recently. Key words Dehydroepiandrosterone • Intracrinology • Hormone replacement therapy • Steroids Introduction functions: 1) DHEA is an endogenous metabolite that cannot be patented so that pharmaceutical companies are In 1934 Butenandt and Dannenbaum isolated not interested in supporting research in this field. dehydroepiandrosterone (DHEA) from urine and in 1944 2) DHEA can be described as a “human molecule” Munson and colleagues identified its 3β-sulphate because other investigated species have much lower (DHEAS). Even now, nearly 70 years later, we still do concentrations.
    [Show full text]
  • Spironolactone 2021 Newborn Use Only
    Spironolactone 2021 Newborn use only Alert Spironolactone is a potassium-sparing diuretic and concomitant intake of potassium or ACE inhibitors may lead to hyperkalemia. Indication Diuretic primarily prescribed for its potassium-sparing effect. For heart failure, in conjunction with furosemide. For chronic lung disease, in conjunction with a thiazide diuretic. Bartter syndrome and Gitelman Syndrome. Action Spironolactone is a synthetic steroid that acts as a competitive aldosterone receptor antagonist, so inhibits sodium reabsorption and spares potassium. It is a weak diuretic. It also inhibits the interaction between dihydrotestosterone and the intracellular androgen receptor resulting in moderate antiandrogenic activity. Drug type Non-selective mineralocorticoid receptor antagonist. Trade name Aldactone; Spiractin Presentation Oral suspension prepared in pharmacy: 1 mg/mL; 2.5 mg/mL; 5 mg/mL. Dose 1–3 mg/kg/dose 24 hourly. Dose can be divided into different intervals. Dose adjustment Therapeutic hypothermia – Not applicable. Renal impairment – Refer to precautions section. Hepatic impairment – Refer to precautions section. Maximum dose 3 mg/kg/day Total cumulative dose Route Oral Preparation Oral suspension. Administration Administer undiluted with feeds. Monitoring Serum potassium at regular intervals. Contraindications Hyperkalaemia. Significant renal impairment. Anuria. Adrenal insufficiency. Precautions Use with caution in infants with renal or hepatic impairment. Monitor more frequently if infant is also given potassium. Drug interactions Spironolactone increases the effects of ACE inhibitors (leading to hyperkalemia), digoxin and sotalol. Adverse reactions Hyperkalaemia and metabolic acidosis. Antiandrogenic effects include reduced hirsutism and gynecomastia. There is one case report of an ovarian cyst in a neonate on spironolactone. Spironolactone interferes with 17-hydroxyprogesterone measurement, which is used to screen neonates for congenital adrenal hyperplasia.
    [Show full text]
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue
    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
    [Show full text]
  • UPLC-MS/MS Analysis of Dihydrotestosterone, Dehydroepiandrosterone, Testosterone, Androstenedione, 17-Hydroxyprogesterone
    [ APPLICATION NOTE ] UPLC-MS/MS Analysis of Dihydrotestosterone, Dehydroepiandrosterone, Testosterone, Androstenedione, 17-Hydroxyprogesterone, and Progesterone in Serum for Clinical Research Dominic Foley and Lisa Calton Waters Corporation, Wilmslow, UK APPLICATION BENEFITS INTRODUCTION ■■ Analytical selectivity of the Steroid hormones encompass a large class of small molecules that play a central chromatographic method provides role in metabolic processes, such as regulation of sexual characteristics, blood separation of isobaric species pressure, and inflammation. Measurement of these steroids by immunoassay can be prone to analytical interference as a result of cross reactivity of ■■ UPLC-MS/MS enables high sample-throughput using reagent antibodies with structurally related steroid hormones and synthetic multi-well plate automation derivatives. UltraPerformance LC™ - tandem mass spectrometry–tandem mass spectrometry (UPLC-MS/MS) can provide analytically sensitive, ■■ Excellent agreement to EQA accurate, and precise measurement of these steroid hormones. mean values for testosterone, androstenedione, 17-OHP, Here we describe a clinical research method utilizing Oasis MAX and DHT µElution Plate technology for the extraction of Dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA), testosterone, androstenedione, 17-Hydroxyprogesterone (17-OHP), and progesterone from serum, which has been automated using the Tecan Freedom EVO 100/4 liquid handler. Chromatographic separation was performed on an ACQUITY UPLC I-Class System using a CORTECS UPLC C18 Column, followed by detection on WATERS SOLUTIONS a Xevo TQ-S micro Mass Spectrometer (Figure 1). In addition, we have Oasis™ MAX µElution Plate examined External Quality Assessment (EQA) samples for testosterone, androstenedione, 17-OHP, and DHT to evaluate the bias and therefore CORTECS™ UPLC™ C18 Column suitability of the method for analyzing these steroids for clinical research.
    [Show full text]
  • Binding of Androgen- and Estrogen-Like Flavonoids to Their Cognate (Non)Nuclear Receptors: a Comparison by Computational Prediction
    molecules Article Binding of Androgen- and Estrogen-Like Flavonoids to Their Cognate (Non)Nuclear Receptors: A Comparison by Computational Prediction Giulia D’Arrigo 1, Eleonora Gianquinto 1, Giulia Rossetti 2,3,4 , Gabriele Cruciani 5, Stefano Lorenzetti 6,* and Francesca Spyrakis 1,* 1 Department of Drug Science and Technology, University of Turin, Via Giuria 9, 10125 Turin, Italy; [email protected] (G.D.); [email protected] (E.G.) 2 Institute for Neuroscience and Medicine (INM-9) and Institute for Advanced Simulations (IAS-5) “Computational Biomedicine”, Forschungszentrum Jülich, 52425 Jülich, Germany 3 Jülich Supercomputing Center (JSC), Forschungszentrum Jülich, 52425 Jülich, Germany 4 Department of Neurology, RWTH, Aachen University, 52074 Aachen, Germany; [email protected] 5 Department of Chemistry, Biology and Biotechnology, University of Perugia, 06123 Perugia, Italy; [email protected] 6 Istituto Superiore di Sanità (ISS), Department of Food Safety, Nutrition and Veterinary Public Health, Viale Regina Elena 299, 00161 Rome, Italy * Correspondence: [email protected] (S.L.); [email protected] (F.S.) Abstract: Flavonoids are plant bioactives that are recognized as hormone-like polyphenols because of Citation: D’Arrigo, G.; Gianquinto, their similarity to the endogenous sex steroids 17β-estradiol and testosterone, and to their estrogen- E.; Rossetti, G.; Cruciani, G.; and androgen-like activity. Most efforts to verify flavonoid binding to nuclear receptors (NRs) and Lorenzetti, S.; Spyrakis, F. Binding of explain their action have been focused on ERα, while less attention has been paid to other nuclear Androgen- and Estrogen-Like and non-nuclear membrane androgen and estrogen receptors. Here, we investigate six flavonoids Flavonoids to Their Cognate (apigenin, genistein, luteolin, naringenin, quercetin, and resveratrol) that are widely present in fruits (Non)Nuclear Receptors: A and vegetables, and often used as replacement therapy in menopause.
    [Show full text]
  • Don't Let Your Hair Down
    Hair ™ Patent N° WO 00/58347 PROCAPIL Don't let your Biotinyl-GHK, citrus and olive tree leaves hair down Function: Fights follicle ageing and protects against hair loss. Definition: Combination of a vitamin fortified matrikine™ (biotinyl-GHK) with apigenin (a flavonoid from citrus) and oleanolic acid from olive tree leaves. Properties: PROCAPILTM targets the main causes of alopecia: poor scalp micro-circulation, follicle ageing and follicle atrophy caused by dihydrotestosterone. Characteristics: Biotinyl-GHK stimulates cell metabolism, apigenin improves micro-circulation and oleanolic acid inhibits 5α-reductase. INCI name: Butylene Glycol – Water (Aqua) – PPG-26-Buteth-26 – PEG-40 Hydrogenated Castor Oil – Apigenin – Oleanolic Acid – Biotinoyl Tripeptide-1 Applications: Hair care products: shampoos, conditioners, leave-on, hair lotions, masks... Formulation: Fortifies Water soluble. Incorporate at 45°C in emulsions or at room temperature in gels. Rejuvenates Recommended use level: 1% to 2% Fights against hair loss Member of Croda International Plc Copyright© 2006 Sederma. All rights reserved. www.sederma.fr E-mail: [email protected] CLAIM SUBSTANTIATION April 2004 Stimulation of cell metabolism In vitro Examples of activated genes by PROCAPILTM Mitosis rate Gene Activity Activation Evaluation of root sheath keratinocytes after a Laminin binding protein Adhesion +146% 14-day culture of hair follicles. Biotiny-GHK (2 ppm) stimulates Ki-67 expression, indicating enhanced cell Acetyl CoA transferase Cell metabolism +137% proliferation. Cytokeratins 10 Differentiation +154% Gene expression Morphological observation PROCAPILTM promotes the expression of numerous control PROCAPILTM genes involved in tissue repair mechanisms (DNA-array on 3D SkinEthic® epidermis). Hair Root sheath Hair anchoring Hair follicles are incubated for 14 days with biotinyl-GHK Dermis / Root sheath (2 ppm).
    [Show full text]
  • Metabolism of Androstenone, 17Β- Estradiol and Dihydrotestosterone
    Metabolism of Androstenone, 17β- Estradiol and Dihydrotestosterone in Primary Cultured Pig Hepatocytes and the Role of 3β-Hydroxysteroid Dehydrogenase in This Process Chen, G. , Zhu, D. , Li, Y. , Bai, Y. , Fang, M. , Ren, L. and Al- Kateb, H. Published PDF deposited in Curve February 2016 Original citation: Chen, G. , Zhu, D. , Li, Y. , Bai, Y. , Fang, M. , Ren, L. and Al-Kateb, H. (2015) Metabolism of Androstenone, 17β-Estradiol and Dihydrotestosterone in Primary Cultured Pig Hepatocytes and the Role of 3β-Hydroxysteroid Dehydrogenase in This Process. PLoS ONE, volume 10 (1): e113194 URL: http://dx.doi.org/10.1371/journal.pone.0113194 DOI: 10.1371/journal.pone.0113194 Publisher: Public Library of Science This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders. CURVE is the Institutional Repository for Coventry University http://curve.coventry.ac.uk/open Metabolism of Androstenone, 17b-Estradiol
    [Show full text]
  • View the Active Ingredients List
    Active Ingredients Anti-Aging is a complicated market; at Ethica we believe in sharing the ingredients work with, so our customers can understand the products they are using. All the marketing in the world means nothing without the correct formulation. We do not “fairy dust” our products to say something is in there, if it is not providing a result that is backed by clinical studies, we leave it out. We are open with our ingredients, why they are there and what they do. Anti-Aging and hair regrowth is extremely complicated and technical, there is no single ingredient that is the perfect solution, that is why using a precise combination of the correct ingredients will yield maximum results across multiple pathways for the broadest range of people. Lets take a look at many of our advanced ingredients: Adenosine Emu Oil Performs similar to 5% minoxidil for hair loss, recent scientif- A powerful anti-inflammatory, emu oil is also very highly ic studies have also show that Adenosine, which is native to absorbent. Emu Oil has also been shown to be a strong the human body, in comparison to Minoxidil and Finasteride, 5 alpha reductase inhibitor or DHT, in target tissues when has no side effects. A 12-month usage of Adenosine leads topically applied to an improvement of hair condition in 84% of all cases Extrapone Rooibos Anageline Extrapone® Rooibos GW (by Symrise) acts as an antioxi- ANAGELINE® is extracted from sweet white lupine. Rich dant. It is a plant extract derived from Aspalathus Linearis in glutaminated peptides, oligo-elements and vitamins, it and possesses anti-aging, anti-allergenic, antimicrobial, pro- controls the hair cycle by regulating the hormonal balance, tective and skin soothing properties.
    [Show full text]
  • Documentation, Codebook, and Frequencies
    Documentation, Codebook, and Frequencies Surplus Sera Laboratory Component: Racial/Ethnic Variation In Sex Steroid Hormone Concentrations Across Age In US Men Survey Years: 1988 to 1991 SAS Export File: SSHORMON.XPT First Published: October 2006 Last revised: N/A NHANES III Data Documentation Laboratory Assessment: Racial/Ethnic Variation in Sex Steroid Hormone Concentrations Across Age In US Men (NHANES III Surplus Sera) Years of Coverage: 1988-1991 First Published: October 2006 Last Revised: N/A Introduction It has been proposed that racial/ethnic variation in prostate cancer incidence may be, in part, due to racial/ethnic variation in sex steroid hormone levels. However, it remains unclear whether in the US population circulating concentrations of sex steroid hormones vary by race/ethnicity. To address this, concentrations of testosterone, sex hormone binding globulin, androstanediol glucuronide (a metabolite of dihydrotestosterone) and estradiol were measured in stored serum specimens from men examined in the morning sample of the first phase of NHANES III (1988-1991). This data file contains results of the testing of 1637 males age 12 or more years who participated in the morning examination of phase 1 of NHANES III and for whom serum was still available in the repository. Data Documentation for each of these four components is given in sections below. I. Testosterone Component Summary Description The androgen testosterone (17β -hydroxyandrostenone) has a molecular weight of 288 daltons. In men, testosterone is synthesized almost exclusively by the Leydig cells of the testes. The secretion of testosterone is regulated by luteinizing hormone (LH), and is subject to negative feedback via the pituitary and hypothalamus.
    [Show full text]
  • (SOGC) Clinical Practice Guideline
    Journal of Obstetrics and Gynaecology Canada The official voice of reproductive health care in Canada Le porte-parole officiel des soins génésiques au Canada Journal d’obstétrique et gynécologie du Canada Volume 36, Number 9 • volume 36, numéro 9 September • septembre 2014 Supplement 2 • supplément 2 Abstract . S1 Chapter 1: Assessment and Risk Management of Menopausal Women . S6 Chapter 2: Cardiovascular Disease . S16 Chapter 3: Menopausal Hormone Therapy and Breast Cancer . S23 Chapter 4: Vasomotor Symptoms . S31 Chapter 5: Urogenital Health . S35 Chapter 6: Managing Prescription Therapeutic Agents . S42 Chapter 7: Menopause Ongoing Management of Menopausal Women and Those With Special Considerations . S51 Chapter 8: Sexuality and Menopause . S59 Chapter 9: Complementary and Alternative Medicine (CAM) . S74 Publications mailing agreement #40026233. Return undeliverable Canadian copies and change of address notifications to SOGC Subscriptions Services, 780 Echo Dr. Ottawa, Ontario K1S 5R7. Editor-in-Chief / Rédacteur en chef Timothy Rowe CPL Editor / Rédactrice PPP Vyta Senikas Translator / Traducteur Martin Pothier Assistant Editor / Rédactrice adjointe Jane Fairbanks Editorial Assistant / Adjointe à la rédaction Daphne Sams Editorial Office / Bureau de la rédaction Journal of Obstetrics and Gynaecology Canada Room D 405A BC Women's Hospital 4500 Oak Street Vancouver BC V6H 3N1 [email protected] Tel: (604) 875-2424 ext. 5668 Fax: (604) 875-2590 http://www.jogc.com The Journal of Obstetrics and Gynaecology Canada (JOGC) is owned by the Society of Obstetricians and Gynaecologists of Canada (SOGC), published by the Canadian Psychiatric Association (CPA), and printed by The Lowe-Martin Group, Ottawa, ON. Le Journal d’obstétrique et gynécologie du Canada (JOGC), qui relève de la Société des obstétriciens et gynécologues du Canada (SOGC), est publié par l’Association des psychiatres du Canada (APC), et imprimé par The Lowe-Martin Group, Ottawa (Ontario).
    [Show full text]
  • Serum Levels of 3A-Androstanediol Glucuronide in Hirsute and Non Hirsute Women
    European Journal of Endocrinology (1998) 138 421–424 ISSN 0804-4643 Serum levels of 3a-androstanediol glucuronide in hirsute and non hirsute women L Falsetti, B Rosina and D De Fusco Department of Gynaecological Endocrinology, University of Brescia, Italy (Correspondence should be addressed to L Falsetti, Via Tirandi, 13-scala F, 25128 Brescia, Italy) Abstract This study has evaluated the behaviour of 3a-androstanediol glucuronide (3a-diol G) in 170 women of whom 85 had polycystic ovary syndrome (PCOS), 35 had idiopathic hirsutism (IH) and 50 had regular cycles (control group). Of the women with PCOS, 45 were hirsute (PCOS-H) and 40 were non hirsute (PCOS-NH). Women in the control group were not hirsute. Hirsutism was assessed by the same physician using the Ferriman-Gallway score. The body mass index (BMI) was estimated in all of the women. Plasma concentrations of 3a-diol G were elevated only in hirsute patients, both with PCOS and with IH. Even in PCOS-NH, concentrations of 3a-diol G were higher compared with controls (P<0.001), but significantly lower (P < 0.001) than those of the PCOS-H and of the IH groups. The behaviour of 3a- diol G was not affected by BMI. European Journal of Endocrinology 138 421–424 Introduction The aim of our study is to provide further contri- butions to the clinical activity of 3a-diol G by evaluat- Hirsutism, affecting 5–8% of the whole female popula- ing its behaviour in a broad series of normal and tion of fertile age, is an important clinical and hyperandrogenic women, with and without hirsutism.
    [Show full text]
  • Efficacy and Safety of a New Topical Hair Loss-Lotion Containing
    etology sm & o C T r f i o c h l o a l n o r Garre A et al., J Cosmo Trichol 2018, 4:1 g u y o J Journal of Cosmetology & Trichology DOI: 10.4172/2471-9323.1000132 ISSN: 2471-9323 Research Article Open Access Efficacy and Safety of a New Topical Hair Loss-Lotion Containing Oleanolic Acid, Apigenin, Biotinyl Tripeptide-1, Diaminopyrimidine Oxide, Adenosine, Biotin and Ginkgo biloba in Patients with Androgenetic Alopecia and Telogen effluvium: A Six-month Open-Label Prospective Clinical Study Aurora Garre1*, Jaime Piquero2, Carles Trullas1 and Gemma Martinez1 1Innovation and Development, ISDIN S.A., Carrer del Provençals 33, Barcelona 08019, Spain 2Dermatologist Dermik Clinic, Barcelona, Spain *Corresponding author: Aurora Garre, Innovation and Development, ISDIN S.A., Carrer del Provencals, 33, Barcelona 08019, Spain, Tel: +34932402020; Fax: +34932020980; E-mail: [email protected] Received date: March 02, 2018; Accepted date: March 27, 2018; Published date: April 02, 2018 Copyright: © 2018 Garre A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objective: The causes of hair loss are multifactorial; therefore, there are multiple potential targets for treatment, and a combination of different active ingredients can be helpful in managing the condition. Androgenetic alopecia and telogen effluvium comprise two of the main types of hair loss, and differ in their pathophysiology. The objective of the study was to evaluate, in male and female individuals with androgenetic alopecia and telogen effluvium, the safety and efficacy of a new hair loss lotion containing a combination of cosmetic ingredients: oleanolic acid, apigenin, biotinyl tripeptide-1, 2-4diamino pyrimidine-3-oxide, adenosine, Ginkgo biloba, and biotin.
    [Show full text]